Roquefort Therapeutics (LON:ROQ) Trading Down 20.1% – What’s Next?

Roquefort Therapeutics plc (LON:ROQ)’s share price traded down 20.1% during trading on Monday . The stock traded as low as GBX 1.60 and last traded at GBX 1.68. 8,808,104 shares traded hands during trading, an increase of 286% from the average session volume of 2,282,590 shares. The stock had previously closed at GBX 2.10.

Roquefort Therapeutics Stock Performance

The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The firm’s fifty day moving average price is GBX 1.94 and its 200 day moving average price is GBX 1.72. The firm has a market capitalization of £2.55 million, a PE ratio of -2.57 and a beta of 0.05.

Roquefort Therapeutics (LON:ROQ) last issued its earnings results on Tuesday, September 30th. The company reported GBX (0.33) EPS for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 29.57%.

Insider Buying and Selling

In other Roquefort Therapeutics news, insider Dr Darrin Disley acquired 5,000,000 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The shares were purchased at an average price of GBX 170 per share, with a total value of £8,500,000. Corporate insiders own 20.35% of the company’s stock.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.